With the recent progress of molecular analysis, KRAS G12R, BRAF V600E mutation, and KIAA1549::BRAF fusion were identified in TG, and the DNA methylation profile of TG suggests its classification as a distinct entity from other lower grade glioma (LrGG)s [6, 12]. The gene discussed is BRAF; the disease is central nervous system cancer.